Table 1.
Differentially Expressed 2DE Gel Spots Following 4-Week VPA Treatment
| Increased | ||||||
|---|---|---|---|---|---|---|
| Spot # | Protein1 | Accession #2 | pI3 | MW4 | Change Following VPA5 | Protein Function |
| #306 | 14-3-3 Protein ε (YWHAE) | P62258 | 5.10 (4.63) |
32.6 (29.2) |
1.292 ± 0.396 (12/15) |
Signal transduction (apoptosis, transcription, cell cycle) |
| #460 | Peroxiredoxin 2 (PRDX2) | P32119 | 5.81 (5.66) |
20.7 (21.9) |
1.017 ± 0.350 (11/15) |
Antioxidant enzyme; anti-apoptotic |
| Decreased | ||||||
| Spot # | Protein1 | Accession #2 | pI3 | MW4 | Change Following VPA5 | Protein Function |
| #58 | WD-repeat Protein 1 (WDR1, Actin-Interacting Protein 1) | O75083 | 6.87 (6.17) |
72.5 (66.2) |
−0.874 ± 0.338 (11/15) |
Cytoskeletal; modulates actin dynamics |
| #157* | Mitogen Activated Protein Kinase 1 (MAPK1, ERK2) | P28482 | 5.13 (6.67) |
53.8 (40.4) |
−0.510 ± 0.505 (8/15) |
Signal transduction (proliferation, differentiation, survival) |
| #215 | Beta-actin (ACTB) | P60709 | 5.95 (5.29) |
42.4 (41.6) |
−0.735 ± 0.356 (10/15) |
Cytoskeletal; cellular structure; motility |
| #278* | Annexin A1 (ANXA1) | P04083 | 8.48 (6.64) |
36.0 (38.6) |
−0.519 ± 0.437 (9/15) |
Regulates phospholipase A2 activity; involved in diverse cellular processes (exocytosis, differentiation, apoptosis) |
| #382* | Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) | P04406 | 9.07 (8.58) |
27.2 (35.9) |
−1.002 ± 0.468 (9/15) |
Glycolytic enzyme; involved in diverse cellular processes (apoptosis, interaction with cytoskeletal elements) |
| #408¥ | Transforming Protein RhoA (RHOA) | P61586 | 6.31 (5.83) |
25.4 (21.4) |
−1.267 ± 0.507 (10/15) |
GDP/GTP binding protein; involved in diverse cellular processes (maintenance of focal adhesions, cell cycle progression, gene expression) |
| #426¥ | Acidic Leucine-Rich Nuclear Phosphoprotein 32 Family Member B (ANP32B, APRIL) | Q92688 | 4.94 (4.19) |
23.4 (22.3) |
−1.045 ± 0.405 (7/15) |
Nucleocytoplasmic shuttling protein; involved in diverse cellular processes (cell cycle progression, mRNA stability, anti-apoptotic?) |
Protein name with gene name in parentheses
Accession # from UniProt KB/Swiss-Prot Entry (http://us.expasy.org/sprot/)
pI from 2D gels; in parentheses, predicted pI from Swiss-Prot
MW (kDa) from 2DE gels; in parentheses, average MW from Swiss-Prot
Mean fold change in spot intensity ± SEM (data in parentheses are the total number of subjects with a change in the same direction as the mean change over the total number of subjects).
Spots were chosen based upon a qualitative trend analysis
Spots were chosen for analysis based upon log normalization of the data, followed by single-sample t-test (p<0.05); All other spots were chosen based upon a single-sample t-test (p<0.05). Spot #450 (21.8 kDa; 6.29 pI) gave a good mass spectrum, but was not identifiable.